China's National Medical Products Administration (NMPA) approved Shanghai Junshi Biosciences' (HKG:1877) new drug application (NDA) for its cholesterol ongericimab injection, according to a Sunday filing with the Hong Kon bourse.
The drug is meant for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia.
The pharmaceutical stocks were down nearly 5% in Hong Kong and 1% in Shanghai in recent trading.
Price (HKD): $14.58, Change: $-0.72, Percent Change: -4.71%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments